Back to School: How biopharma can reboot drug development. Access exclusive analysis here
KG said it submitted a Citizen's Petition to FDA asserting that ZGEN has not provided the agency with adequate data
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury